Immunic, Inc.IMUXNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

proactiveinvestors.com

Immunic secures European patent for MS drug candidate vidofludimus calcium

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Tuesday the European Patent Office has granted a key patent covering dosing regimens for its experimental multiple sclerosis treatment vidofludimus calcium, extending potential market protection for the drug candidate in Europe to 2038. The patent, EP3713554, protects label-relevant dosing regimens of vidofludimus calcium and broadly covers the compound and its salt, solvate and free acid forms when used according to the approved label, the company said.

prnewswire.com

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 – – Broad Protection Extends to All Forms of Vidofludimus, Including Its Salts, Solvates and Free Acid – – Multi-Layered Intellectual Property Strategy Expected to Provide Protection at Least Into 2041 in the United States and Into 2039 in Europe – NEW YORK, March 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that the European Patent Office (EPO) has granted a key European patent, EP3713554, directed to label-relevant dosing regimens of lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838). The patent is expected to provide protection for vidofludimus calcium in Europe into 2038, and may be eligible for a Supplementary Protection Certificate (SPC), which could extend market exclusivity potentially into 2043.

defenseworld.net

Critical Analysis: Immunic (NASDAQ:IMUX) and Neuphoria Therapeutics (NASDAQ:NEUP)

Immunic (NASDAQ: IMUX - Get Free Report) and Neuphoria Therapeutics (NASDAQ: NEUP - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Profitability This table compares Immunic and Neuphoria Therapeutics'

proactiveinvestors.com

Immunic to present at healthcare investor conferences in March

Immunic Inc (NASDAQ:IMUX), a late-stage biotechnology company developing oral treatments for neurological and gastrointestinal diseases, will participate in two investor conferences this month. Chief executive Daniel Vitt and president Jason Tardio will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami on 11 March, with one-on-one investor meetings also scheduled across the event, which runs from 8 to 11 March.

proactiveinvestors.com

UBS raises memory chip price targets as supply crunch deepens, defying sector sell-off

The bank now forecasts DDR contract prices rising 72% in the first quarter alone, with undersupply expected to persist into 2028 Wall Street's retreat from...

prnewswire.com

Immunic to Participate in Investor Conferences in March

NEW YORK, March 3, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following investor conferences in March: March 8-11: Leerink Partners Global Healthcare Conference. Daniel Vitt, Ph.D.

proactiveinvestors.com

FTSE 100 Live: London sell-off may be 'muted' as markets react to Iran war

7.56am: IHG included in hotel competition probe The Competition and Markets Authority has launched an investigation into Intercontinental Hotels,...

proactiveinvestors.com

Immunic secures $400M to support late-stage MS trials - ICYMI

Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support completion of late-stage trials and prepare the company for a potential commercial launch of vidofludimus calcium in multiple sclerosis. Speaking to Proactive, CEO Dr Daniel Vitt described the financing as “a transformative transaction for the company,” noting that $200 million has already been received, with the remainder available in a second tranche.

proactiveinvestors.com

Immunic secures $400M to support late-stage MS trials - ICYMI

Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support completion of late-stage...

proactiveinvestors.com

Immunic sets stage for phase 3 MS data readout after $400M financing

Immunic Inc (NASDAQ:IMUX) said it is entering a pivotal period for its multiple sclerosis program after securing up to $400 million in new financing and advancing its lead drug into late-stage development, with key data expected by the end of 2026. The biotechnology company's oral candidate, vidofludimus calcium (IMU-838), is currently being evaluated in the twin phase 3 ENSURE-1 and ENSURE-2 trials in relapsing multiple sclerosis (RMS).

prnewswire.com

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million – – Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Transition into a Commercial Organization – NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the year ended December 31, 2025, and provided a corporate update. "The phase 3 ENSURE-1 and ENSURE-2 trials of our lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (RMS) continue to progress, with top-line data expected to be available by the end of 2026," stated Daniel Vitt, Ph.D.

defenseworld.net

Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of “Buy” from Analysts

Shares of Immunic, Inc. (NASDAQ: IMUX - Get Free Report) have been given a consensus rating of "Buy" by the nine analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and three have assigned a strong buy rating to

proactiveinvestors.com

FTSE 100 Live: Index powers to new highs as CPI falls, miners and defence in demand

FTSE 100 climbs 108 points to 10,665 BAE Systems and Glencore lead risers after results Inflation eases to further raise BoE rate cut hopes 12.09am: FTSE...

proactiveinvestors.com

Immunic closes $200M private placement to fund late-stage MS trials

Immunic Inc (NASDAQ:IMUX) said on Tuesday it has closed a previously disclosed private placement financing, raising $200 million upfront with the potential to secure up to an additional $200 million. The New York-based biotechnology company issued just over 229 million pre-funded warrants at a price of $0.873 each, generating gross upfront proceeds of $200 million.

prnewswire.com

Immunic Announces Closing of Oversubscribed Private Placement Financing

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis, and Begin of Transition Into a Commercial Organization – NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the closing of its previously disclosed private placement financing. The financing was led by BVF Partners L.P.

proactiveinvestors.com

Immunic closes $200M private placement to fund late-stage MS trials

Immunic Inc (NASDAQ:IMUX) said on Tuesday it has closed a previously disclosed private placement financing, raising $200 million upfront with the potential...

proactiveinvestors.com

Immunic MS trial shows reduced brain lesions - ICYMI

Immunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about new data presented at the ACTRIMS Forum in San Diego, highlighting findings from the company's phase 2 CALIPER trial in progressive multiple sclerosis (MS). Proactive: Hello, you're watching Proactive.

proactiveinvestors.com

Immunic MS trial shows reduced brain lesions - ICYMI

Immunic Inc (NASDAQ:IMUX)’s chief medical officer Dr Andreas Muehler talked with Proactive about new data presented at the ACTRIMS Forum in San Diego,...

benzinga.com

Immunic Stock Jumps After Pricing $400 Million Private Placement

Immunic Inc (NASDAQ: IMUX) is surging Friday after the late‑stage biotech announced a private placement of up to $400 million.

proactiveinvestors.com

Immunic to raise up to $400M to fund late-stage MS trials, commercial push

Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the biotechnology company works to transition toward commercialization of its multiple sclerosis pipeline. The financing includes $200 million in upfront proceeds through the issuance of 229,076,000 pre-funded warrants priced at $0.873 each, with the potential for an additional $200 million from accompanying warrants if exercised.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance